Pipeline
Developing Assays Across Food Allergens
AllerGenis’ researchers are developing a pipeline of assays across a broad array of food allergens. Founded on the epitope mapping research of Hugh Sampson, MD, of the Jaffe Food Allergy Institute of the Icahn School of Medicine at Mount Sinai, our diagnostic technology subdivides allergenic proteins into smaller peptides, called epitopes, and measures the reactivity of a patient’s IgE to these epitopes. The platform uses a high-throughput, bead-based epitope assay (BBEA) to analyze IgE reactivity to discrete food allergen epitopes from only a few microliters of patient plasma in a CLIA certified, clinical lab setting.
*Epitope Panel Identification
value of Allergenis
Platform is clear
The AllerGenis high throughput multiplex Luminex bead based epitope assay (BBEA) enables clear quantification and the screening of samples and epitopes with smaller volumes of plasma.
The epitope platform is the only diagnostic platform validated against oral food challenge, the gold standard for allergy diagnostics.
Blood-based epitope mapping is performed without the risk of triggering an allergic reaction and may lessen patient anxiety.
robust technology
In full development, the goal of the AllerGenis
technology program will be the ability to:
- Diagnose patient food allergy and associated disease severity (including anaphylaxis) without the risks associated with oral food challenge.
- Distinguish between a sensitized patient and allergic disease, and who will naturally outgrow.
- Assess progression of desensitization during immunotherapy.
